MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea
(Thomson Reuters ONE) -
MediGene AG / MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, May 10, 2010. The biotech company MediGene AG (Frankfurt,
Prime Standard, TecDAX) has signed two further license and supply agreements for
the commercialization and marketing of Veregen(®). These have been signed with
GC-Rise Pharmaceutical Co., Ltd. in China and JS Bio Pharm Co., Ltd. in South
Korea.
GC-Rise will conduct the clinical trials of Veregen(® )(for the treatment of
genital warts) that are required for approval of the ointment in China, and will
be responsible for all the regulatory and approval procedures thereafter.
MediGene will receive a one-time payment upon execution of the agreement and a
further milestone payment upon initiation of the first clinical trial in China.
In addition, MediGene will profit from supplying GC-Rise with the drug product.
GC-Rise expects market launch in China at the end of 2013.
JS Bio Pharm will promote and distribute Veregen(® )for the treatment of genital
warts, and will also be responsible for all regulatory procedures and for
obtaining approval of the drug in South Korea. MediGene will receive royalties
and a milestone payment contingent on the level of sales achieved. In addition,
MediGene will profit from supplying JS Bio Pharm with the drug product. JS Bio
Pharm expects to launch the drug on the South Korean market during 2012.
MediGene has already entered into marketing partnerships for Veregen(®) with
Nycomed, Inc. for the USA, with Abbott Arzneimittel GmbH (previously Solvay) for
Germany, Austria, and Switzerland, with Juste S.A.Q.F for Spain and Portugal,
with Teva Pharmaceuticals Industries Ltd. for Israel, and with Meditrina
Pharmaceuticals for Greece and Cyprus.
Veregen(®) is currently available on the US and German markets. Approval for
Austria has been granted, and market launch in Austria is planned for the summer
of 2010. A second wave of marketing applications within the European mutual
recognition procedure is expected in the second half of 2010, with Germany
serving as the reference state in this process. In addition MediGene is planning
to conclude further marketing partnerships.
Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "We are delighted to
have found partners for the commercialization of Veregen(®) in these significant
Asian markets. This again shows the high level of interest in this innovative
product. We see great potential in the Asian market and with GC-Rise and JS Bio
Pharm we have well positioned partners with a great expertise in this area."
Veregen(®): Veregen(® )for the topical treatment of external genital warts is a
concentrate of catechins with a complex defined composition, extracted from
green tea leaves. MediGene acquired the basic rights to the active ingredient in
Veregen(®) from the Canadian company Epitome Pharmaceuticals, Inc. in 1999, and
was solely responsible for the drug's successful preclinical and clinical
development, as well as the approval process. Moreover the patent protection has
been further upgraded by a number of proprietary inventions.
GC-Rise: GC-Rise Pharmaceutical Ltd is an emerging speciality pharmaceutical
company, located in Beijing, China, with a focus on women's health. GC-Rise has
a strong sales network across China. GC-Rise has successfully launched several
products in the past year. GC Rise is backed by the international healthcare
investment group Inventages, one of the largest venture capital firms
specializing in life sciences, with more than $1.5 billion under management and
operating on a global basis with offices in North America, Europe and
Australasia. For further information about GC-Rise please see www.gc-rise.com
JS Bio Pharm: JS Bio Pharm is a specialized distributor for pharmaceutical
products, especially European Original products in dermatological and
respiratory fields. JS Bio Pharm has a successful track record in the
registration and marketing of herbal medicines in Korea. JS Bio Pharm is the
spin-off company from Jesam Biozam Co., Ltd founded in 2003 and which is the
Korean representative of PharmIntraco GmbH in Switzerland.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(®) and Veregen(®) are registered trademarks of MediGene AG. These
trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax)
biotechnology company located in Martinsried/Munich, Germany, with subsidiaries
in Oxford, UK and San Diego, USA. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has
several drug candidates in clinical development and possesses innovative
platform technologies. MediGene focuses on clinical research and development of
novel drugs with focus on oncology.
Contact MediGene AG
Email: investor(at)medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
[HUG#1413980]
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Unternehmensinformation / Kurzprofil:
Datum: 10.05.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 20565
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
